KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Weighted Average) (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $79.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1.74% to $79.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Dec 2025, up 1.74% year-over-year, with the annual reading at $79.3 million for FY2025, 1.74% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $79.3 million at Xenon Pharmaceuticals, roughly flat from $79.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $79.3 million in Q4 2025, with the low at $2.3 million in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $53.6 million, with a median of $65.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 95.99% in 2023, then surged 3344.44% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $2.8 million in 2021, then grew by 11.81% to $3.1 million in 2022, then soared by 2055.02% to $66.9 million in 2023, then grew by 16.45% to $77.9 million in 2024, then rose by 1.74% to $79.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $79.3 million, $79.0 million, and $79.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.